Sai Parenteral IPO Details
Sai Parenteral IPO Summary
Sai Parenteral IPO opens for subscription on 24 Mar 2026 and closes on 27 Mar 2026.The IPO will be listed on NSE, BSE with the tentative listing date set for 02 Apr 2026.
Sai Parenteral IPO price band has been fixed at ₹372 – ₹392 per share. The face value is ₹5 per share with a lot size of 38.
Sai Parenteral IPO total issue size comprises 1,04,28,288 shares (aggregating up to ₹408.79 Cr). This includes a fresh issue of 72,70,408 shares (aggregating up to ₹285.00 Cr). Offer for Sale consists of 31,57,880 shares (aggregating up to ₹123.79 Cr). Pre-issue shareholding stands at 3,69,08,823, which will increase to 4,41,79,231 post-issue.
Sai Parenteral IPO carries a ₹0 (0%) GMP, reflecting investor sentiment.
Sai Parenteral IPO Lot Size :Retail Minimum is 1 lot (38 shares) amounting to ₹14,896. Retail Maximum is 13 lots (494 shares) amounting to ₹193,648. SHNI Minimum is 14 lots (532 shares) amounting to ₹208,544. SHNI Maximum is 67 lots (2,546 shares) amounting to ₹998,032. BHNI Minimum is 68 lots (2,584 shares) amounting to ₹1,012,928.
Sai Parenteral IPO Details
Sai Parenteral IPO Dates
- 24 Mar 2026Opening dateOpen
- 27 Mar 2026Closing dateClose
- 30 Mar 2026Allotment Date Allotment
- 01 Apr 2026Initiation of RefundsRefund
- 01 Apr 2026Credit of SharesCredit
- 02 Apr 2026Listing dateListing
Sai Parenteral IPO Lot Size
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Retail Minimum | 1 | 38 | ₹14,896 |
| Retail Maximum | 13 | 494 | ₹193,648 |
| SHNI Minimum | 14 | 532 | ₹208,544 |
| SHNI Maximum | 67 | 2546 | ₹998,032 |
| BHNI Minimum | 68 | 2584 | ₹1,012,928 |
Sai Parenteral IPO Reservation
Promoter Holding
Documents
Sai Parenteral IPO Valuations
Sai Parenteral Financial Information
| Period Ended | 30 Sep 2025 | 31 Mar 2025 | 31 Mar 2024 | 31 Mar 2023 |
|---|---|---|---|---|
| Assets | 376.24 | 272.39 | 268.10 | 133.96 |
| Total Income | 89.43 | 163.74 | 155.18 | 97.03 |
| Profit After Tax | 7.76 | 14.43 | 8.42 | 4.38 |
| EBITDA | 16.24 | 39.44 | 31.70 | 17.64 |
| NET Worth | 209.37 | 95.78 | 76.40 | 31.49 |
| Reserves and Surplus | 188.84 | 80.36 | 61.30 | 24.34 |
| Total Borrowing | 76.07 | 93.95 | 118.79 | 68.55 |
| Amount in ₹ Crore | ||||
About Sai Parenteral IPO
Sai Parenteral's Limited, incorporated in 2001, is a diversified pharmaceutical formulations company with capabilities spanning research, development, and manufacturing of pharmaceutical products.
The company operates across two primary business segments: Branded Generic Formulations and Contract Development and Manufacturing Organisation (CDMO) services, catering to both domestic and international markets.
The company’s product portfolio covers a wide range of therapeutic areas including cardiovascular, neuropsychiatry, anti-diabetic, respiratory health, antibiotics, gastroenterology, vitamins, minerals and supplements (VMS), analgesics, and dermatology. Its offerings are available across multiple dosage forms such as injectables, tablets, capsules, liquid oral formulations, and ointments.
Sai Parenteral's Limited serves a diverse customer base comprising central and state government agencies, pharmaceutical companies, public and private hospitals, and super stockists across India. The company expanded into international markets in Fiscal 2023 following the acquisition of two internationally accredited manufacturing facilities in Hyderabad, Telangana, and currently supplies products to regulated and semi-regulated markets including Australia, New Zealand, Southeast Asia, the Middle East, and Africa.
The company owns and operates five manufacturing facilities in India. Four facilities are located in Hyderabad, Telangana, including a GMP-compliant injectable unit, a WHO-GMP certified injectable unit, a TGA-Australia and PIC/S accredited solid oral dosage unit, and a WHO-GMP certified cephalosporin facility. Additionally, its wholly owned subsidiary, Revat Laboratories, operates a GMP-certified manufacturing facility in Ongole, Andhra Pradesh.
As of December 31, 2025, Sai Parenteral's Limited had a total workforce of 298 full-time employees.
Strength Of Sai Parenteral IPO
- Diversified generic formulations player with an established track record.
- Strategically located and accredited Manufacturing Facilities.
- Strong focus on CDMO business.
- Well-established sales network in India and overseas.
- Track record of value-accretive acquisitions.
- Experienced Promoters and Senior Management with extensive domain knowledge.
Risk Of Sai Parenteral IPO
- The company's Manufacturing Facilities are concentrated in Hyderabad, Telangana and Ongole, Andhra Pradesh. The company is exposed to risks originating from slowdown or shutdown, economic, regulatory, political and other changes in this region, including natural disasters, which could adversely affect its business, results of operations and financial condition.
- Out of its diversified product portfolio, approximately 44.78%, 47.64% and 92.03% during the Fiscals 2025, 2024 and 2023, respectively of the company's Net Revenue from Operations was derived from the sale of injectables. Any reduction in demand for these products may adversely affect its business, financial condition, results of operations and cash flows.
- The company's Manufacturing Facilities are subject to periodic inspections and audits by regulatory authorities and customers. The company may be subject to regulatory action which may damage its reputation, leading to an adverse effect on the company's business, results of operations, financial condition and cash flows.
- Majority of its key raw material purchases, being APIs, excipients and intermediates, are sourced from a diversified supplier base, and the company does not enter into is not any long-term contractual agreements with them. Any reduction of supplies or discontinuation of supplies from its top suppliers could have a material adverse effect on the company's business, financial condition, results of operations and cash flows. Any fluctuation in prices of its raw materials may have a material adverse effect on the company's business, results of operations, prospects and financial condition.
- The company's success depends on its ability to successfully develop and commercialize new products in a timely manner. Any failures to do so could adversely affect the company's business, results of operations and financial condition.
- The company's business is dependent on the sale of products to a limited number of customers for a significant portion of its revenues. The loss of one or more such customers or the deterioration of their financial condition or prospects could adversely affect its business, results of operations and financial condition.
- The company's international business exposes us to complex management, legal, tax and economic risks, which could adversely affect its business, results of operations and financial condition.
- There are outstanding legal proceedings involving the Company, Promoters, some of its Directors and, the company's Material Subsidiary.
- The company plans to expand and/or upgrade its Manufacturing Facilities from the Net Proceeds of the Fresh Issue and will be required to briefly stop operations in Unit I and II till such plans are completed. The company has estimated a period of 6 months for this disruption before both these units can resume operations. The company is also dependent on third-party contractors and specialist agencies who will be executing the proposed expansion and/or upgradation plans.
- The Indian pharmaceutical market is subject to extensive regulation and its failures to comply with the existing and future regulatory requirements in the pharmaceutical market could adversely affect the company's business, results of operations and financial condition.
Objectives Sai Parenteral IPO
1. Capacity expansion and upgradation of manufacturing facilities
2. Establishment of a new R&D Centre;
3. Repayment / prepayment of certain outstanding borrowings
4. Working capital requirements
5. Investment in wholly owned subsidiary, Sai Parenterals Pte Limited (Singapore), in relation to the proposed acquisition of Noumed Pharmaceuticals Pty Limited (Australia); and
6. General corporate purposes
7. Total
Company Contact Details
Sai Parenteral's Ltd.
Plot No 39
5th floor, Lavanya Arcade Jayabheri Enclave
Gachibowli, K.V.Rangareddy, Seri Lingampally
Hyderabad, Telangana, 500032
Phone: +91 79979 91301
Email: cs@saiparenterals.com
Website: https://www.saiparenterals.com/
Registrar Contact Details
Sai Parenteral FAQs
The Sai Parenteral IPO is a MAINBOARD public issue comprising 10428288 equity shares with a face value of ₹5 each, aggregating to a total issue size of ₹408.79 Cr. The issue price has been fixed at ₹392 per equity share, and the minimum application size is 38 shares.
The IPO opens for subscription on 24 Mar 2026, and closes on 27 Mar 2026.
Bigshare Services Pvt Ltd has been appointed as the registrar to the issue. The equity shares are proposed to be listed on the Bombay Stock Exchange (BSE) and the National Stock Exchange (NSE).
As of now, the current GMP stands at ₹0 (0%).
Quick Links
Comments
